The efficacy of citalopram in depression and quality of life in the patients with cardiac disease

The efficacy of citalopram in depression and quality of life in patients with acute coronary syndrome

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091722991N6

Enrollment

Registered

2016-09-30

Start date

2015-09-23

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Acute Coronary Syndrome. Condition 2: Acute Coronary Syndrome. Unstable Angina Acute Myocardial Infarction

Interventions

Intervention 1: Intervention group: Ramopharmin drug company citalopram tablets 20 milligram daily for 8 weeks. Intervention 2: Control group: weekly psychiatric visit without any antidepressant drug

Treatment - Drugs

Intervention group: Ramopharmin drug company citalopram tablets 20 milligram daily for 8 weeks

Control group: weekly psychiatric visit without any antidepressant drug for 8 weeks

Eligibility

Sex/Gender

All

Age

18 Years to 100 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: admission in cardiac care units because of acute coronary syndrome; age more than 18 years; women in reproductive ages who are not pregnant and do not want to have pregnancy in duration of the study; assignment the informed consent form of the study Exclusion criteria: past history of intolerance to selective serotonin reuptake inhibitors; severe and life threatening medical conditions which inhibit the participation of the patient in duration of the study; severe congestive heart failure with diagnosis of the cardiologist; dependence to alcohol or other addictive drugs; psychosis or dementia or mental retardation in patient; pregnancy and breast feeding; history of elevated mood

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Patient´s depressive condition. Timepoint: 3th and 8th weeks after treatment. Method of measurement: Hospital Anxiety and Depression Scale.;Patient´s quality of life. Timepoint: 3th and 8th weeks after treatment. Method of measurement: SF-36 Quality of Life Questionnaire.	—

Secondary

Measure	Time frame
Adverse drug reaction. Timepoint: 3rd and 8th weeks after treatment. Method of measurement: psychiatric visit.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSussan Moudi, MD

Babol University of Medical Sciences

sussan.mouodi@gmail.com+98 11323268823

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026